Inhibrx Biosciences Inc(INBX)
$83.30-4.45 (-5.07%)
INBX
Inhibrx Biosciences Inc financials statements
$83.30
At close:-4.45 (-5.07%)
Want to see INBX full AI Analyst Report?
Inhibrx Biosciences Inc (INBX) Ratios
123 Followers
Inhibrx Biosciences Inc Ratios
INBX's free cash flow for Q3 2026 was $-34.66M. For the 2026 fiscal year, INBX's free cash flow was decreased by $-56.00K and operating cash flow was $-34.60M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.93 | 3.94 | 5.25 | 10.17 | 6.20 |
| Quick Ratio | 3.93 | 3.94 | 5.25 | 10.17 | 6.23 |
| Cash Ratio | 3.68 | 3.75 | 4.94 | 9.93 | 5.85 |
| Solvency Ratio | -0.99 | 35.81 | -0.91 | -0.62 | -0.82 |
| Operating Cash Flow Ratio | -3.84 | -4.77 | -3.43 | -4.18 | -3.58 |
| Short-Term Operating Cash Flow Coverage | -55.80 | -121.89 | 0.00 | -61.99 | -47.98 |
| Net Current Asset Value | $ -5.65M | $ 113.22M | $ 30.97M | $ 47.67M | $ 41.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.73 | 0.04 | 0.68 | 0.71 | 0.48 |
| Debt-to-Equity Ratio | 13.39 | 0.06 | 4.83 | 3.57 | 1.38 |
| Debt-to-Capital Ratio | 0.93 | 0.06 | 0.83 | 0.78 | 0.58 |
| Long-Term Debt-to-Capital Ratio | 0.93 | 0.00 | 0.83 | 0.78 | 0.57 |
| Financial Leverage Ratio | 18.33 | 1.35 | 7.08 | 5.01 | 2.87 |
| Debt Service Coverage Ratio | -8.63 | 112.91 | -6.49 | -7.00 | -10.94 |
| Interest Coverage Ratio | -11.07 | -24.57 | -6.89 | -8.02 | -14.68 |
| Debt to Market Cap | 0.08 | 0.01 | 0.12 | 0.21 | 0.04 |
| Interest Debt Per Share | 7.70 | 1.49 | 5.13 | 5.57 | 2.04 |
| Net Debt to EBITDA | 0.14 | -0.08 | 0.33 | 0.53 | 0.78 |
| Profitability Margins | |||||
| Gross Profit Margin | -91.00% | -1042.50% | 33.83% | -4926.73% | 62.27% |
| EBIT Margin | -9835.15% | 850532.50% | -11549.11% | -5795.71% | -1074.58% |
| EBITDA Margin | -9644.15% | 851675.00% | -11482.94% | -5739.83% | -1057.81% |
| Operating Profit Margin | -10386.54% | -165724.00% | -12178.94% | -5890.37% | -1074.58% |
| Pretax Profit Margin | -10773.31% | 843787.00% | -13318.00% | -6625.14% | -1147.59% |
| Net Profit Margin | -10773.46% | 843786.00% | -13408.94% | -6625.27% | -1147.62% |
| Continuous Operations Profit Margin | -10773.46% | 843786.00% | -13318.17% | -6625.27% | -1147.62% |
| Net Income Per EBT | 100.00% | 100.00% | 100.68% | 100.00% | 100.00% |
| EBT Per EBIT | 103.72% | -509.15% | 109.35% | 112.47% | 106.79% |
| Return on Assets (ROA) | -95.62% | 933.56% | -78.39% | -49.93% | -54.35% |
| Return on Equity (ROE) | -1752.22% | 1263.30% | -554.81% | -250.14% | -156.10% |
| Return on Capital Employed (ROCE) | -119.83% | -236.69% | -87.14% | -49.04% | -59.82% |
| Return on Invested Capital (ROIC) | -117.41% | -234.02% | -86.43% | -48.69% | -59.05% |
| Return on Tangible Assets | -95.62% | 933.56% | -78.39% | -49.93% | -54.35% |
| Earnings Yield | -11.45% | 757.00% | -13.48% | -14.70% | -4.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.34 | 0.48 | 2.31 | 8.53 | 8.12 |
| Payables Turnover | 0.42 | 0.25 | 0.11 | 13.23 | 0.29 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | -3.06 |
| Fixed Asset Turnover | 0.14 | 0.01 | 0.19 | 0.30 | 0.75 |
| Asset Turnover | 0.01 | 0.00 | 0.01 | 0.01 | 0.05 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.07 |
| Cash Conversion Cycle | -824.07 | -710.27 | -3199.26 | 15.21 | -1313.32 |
| Days of Sales Outstanding | 49.70 | 766.50 | 157.76 | 42.79 | 44.98 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | -119.22 |
| Days of Payables Outstanding | 873.77 | 1476.77 | 3357.02 | 27.58 | 1239.07 |
| Operating Cycle | 49.70 | 766.50 | 157.76 | 42.79 | -74.24 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.38 | -13.43 | -4.10 | -2.87 | -2.11 |
| Free Cash Flow Per Share | -8.38 | -13.61 | -4.20 | -2.89 | -2.14 |
| Dividend Paid and CapEx Coverage Ratio | -4186.90 | -13.05 | -42.09 | -168.08 | -92.97 |
| Capital Expenditure Coverage Ratio | -4186.90 | -74.86 | -42.09 | -168.08 | -92.97 |
| Operating Cash Flow Coverage Ratio | -1.21 | -24.16 | -0.92 | -0.56 | -1.11 |
| Operating Cash Flow to Sales Ratio | -99.84 | -972.04 | -107.39 | -52.60 | -11.27 |
| Free Cash Flow Yield | -10.61% | -88.37% | -11.05% | -11.74% | -4.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.74 | 0.13 | -7.42 | -6.80 | -20.30 |
| Price-to-Sales (P/S) Ratio | 941.13 | 1114.64 | 994.97 | 450.85 | 232.97 |
| Price-to-Book (P/B) Ratio | 153.07 | 1.67 | 41.17 | 17.02 | 31.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.42 | -1.13 | -9.05 | -8.52 | -20.45 |
| Price-to-Operating Cash Flow Ratio | -9.43 | -1.15 | -9.26 | -8.57 | -20.67 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | -0.00 | -0.18 | -0.10 | 0.72 |
| Enterprise Value Multiple | -9.62 | 0.05 | -8.34 | -7.32 | -21.24 |
| Enterprise Value | 1.21B | 78.38M | 1.72B | 921.50M | 1.60B |
| EV to EBITDA | -9.62 | 0.05 | -8.34 | -7.32 | -21.24 |
| EV to Sales | 927.90 | 391.90 | 957.31 | 420.39 | 224.67 |
| EV to Free Cash Flow | -9.29 | -0.40 | -8.71 | -7.94 | -19.72 |
| EV to Operating Cash Flow | -9.29 | -0.40 | -8.91 | -7.99 | -19.93 |
| Tangible Book Value Per Share | 0.52 | 9.23 | 0.92 | 1.45 | 1.38 |
| Shareholders’ Equity Per Share | 0.52 | 9.23 | 0.92 | 1.45 | 1.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.08 | 0.01 | 0.04 | 0.05 | 0.19 |
| Net Income Per Share | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 |
| Tax Burden | 1.00 | 1.00 | 1.01 | 1.00 | 1.00 |
| Interest Burden | 1.10 | 0.99 | 1.15 | 1.14 | 1.07 |
| Research & Development to Revenue | 86.94 | 1018.72 | 105.92 | 50.27 | 10.03 |
| SG&A to Revenue | 17.92 | 639.52 | 16.32 | 9.64 | 1.73 |
| Stock-Based Compensation to Revenue | 8.57 | 292.59 | 13.80 | 9.33 | 2.11 |
| Income Quality | 0.93 | -0.12 | 0.81 | 0.79 | 0.98 |
Currency in USD
